LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- The global active implantable devices are experiencing tremendous growth, cites a new report by Meticulous Research™. According to the research report titled as ‘Active Implantable Devices Market – Global Opportunity Analysis and Industry Forecast (2017-2022)’, the active implantable devices market will reach $24.02 billion by 2022, growing at a CAGR of 6.7% during the next five years.
“The global active implantable devices market is driven by increasing incidence & prevalence of cardiovascular diseases, technological advancements, increasing prevalence of neurological diseases with growing age, and expanded application of neurostimulators in chronic pain therapy,” mentions Meticulous Research™.
The report notes that the Implantable cardioverter defibrillators held the largest share of active implantable devices in 2016, primarily due to rising adoption of ICDs for the prevention of sudden cardiac deaths (SCD) in patients at high risk for SCD with increasing incidence of cardiac arrest and atrial fibrillation, and growing burden of patients with high blood pressure.
Request Sample Report: http://www.meticulousresearch.com/request-sample-report/?cp_id=3539
North America (mainly U.S and Canada) currently have the largest share of the active implantable devices market, “due to increasing incidence of cardiovascular diseases and neurological disorders with rising greying population, and expanded application of neurostimulators for chronic pain therapy; well-established healthcare system & distribution channel; higher spending on healthcare; and presence of leading players in this market.” But the research report also notes that Asia Pacific should see exponential growth in the active implantable devices market within the next five years.
The global active implantable devices market is highly consolidated with the top three players namely Medtronic plc (Ireland), Abbott Laboratories (U.S.), and Boston Scientific Corporation (U.S.) together holding around three-fourth share of this market. The other key players in the global active implantable devices market are BIOTRONIK SE & Co. KG , LivaNova PLC, Cochlear Limited, MED-EL, Sonova Holding AG, William Demant Holding A/S, and Nurotron Biotechnology Co., Ltd.
Full News: http://www.meticulousresearch.com/active-implantable-devices-market-forecast/
Scope of the Report:
Market by Product:
• Implantable Cardioverter Defibrillators
- Transvenous Implantable Cardioverter Defibrillators
- Biventricular Implantable Cardioverter Defibrillators
- Dual-Chamber Implantable Cardioverter Defibrillators
- Single-Chamber Implantable Cardioverter Defibrillators - Subcutaneous Implantable Cardioverter Defibrillators
• Implantable Cardiac Pacemakers
• Ventricular Assist Devices
• Implantable Heart Monitors/Insertable Loop Recorders
• Implantable hearing devices
• Neurostimulators
- Spinal Cord Stimulators
- Deep Brain Stimulators
- Sacral Nerve Stimulators
- Vagus Nerve Stimulators
- Gastric Electrical Stimulators
Browse in-depth report on http://www.meticulousresearch.com/product/active-implantable-devices-market-2022/
Contact Info:
Viren Shrivastava
AVP- Global Sales and Marketing
Meticulous Research™
Email: viren@meticulousresearch.com
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)
+91 744-7780008 (Asia-Pacific)